Updated:
Majycc eSante Invest
Paris-based early-stage investment firm exclusively backing digital health startups at seed and start-up stages across the European market.
Majycc eSante Invest
Founded in Paris and focused entirely on e-health, Majycc eSante Invest emerged to back the earliest stages of France's digital health transformation. The firm writes initial cheques into seed and start-up rounds, backing founders who are building clinical-grade software, telemedicine platforms, and data-driven patient-management tools. Its single-sector commitment means every investment sits inside one thesis: that Europe's regulated healthcare systems are ripe for digital-layer disruption. Majycc eSante targets pre-revenue and early-traction digital health companies, typically funding rounds below €2 million. The firm takes direct equity positions rather than operating as a fund-of-funds, building a concentrated portfolio of French and European companies that sit at the regulatory intersection of medical device and software-as-a-service business models. Its geographic focus spans France, Belgium, Switzerland, and francophone North Africa — regions where reimbursement codes and hospital procurement cycles reward clinical validation over consumer growth hacking. The investment posture is patient and deeply sector-specific: a typical holding period extends through the clinical-certification milestones that deter generalist venture funds. Majycc eSante's small-team structure reflects its specialist mandate. Operating from a single Paris office, the firm relies on a network of clinician-advisors and hospital-system relationships to source deals that rarely appear on open platforms. France's digital health ecosystem — anchored by the government's "Ma Santé 2022" program and subsequent e-health acceleration plans — creates a policy-driven deal pipeline for a firm that can underwrite both the technology and the regulatory pathway. The firm's website (majycc.com) positions it as a pure-play digital health vehicle, a rarity even in Paris's growing deeptech and life-sciences funding community. What structurally differentiates Majycc eSante Invest is its complete refusal to diversify outside a single regulated vertical. Most early-stage funds in Europe spread across digital, deeptech, and life sciences to hedge binary regulatory risk; Majycc eSante concentrates that risk, betting that domain depth beats portfolio breadth in a sector where regulatory gatekeeping rewards genuine expertise.
General information
Firm type
Private Equity Firm
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
France
City
Paris
Corporate office
Paris, France
Sector focus
Frequently asked questions
What investment stages does Majycc eSante Invest target?
The firm targets early-stage companies, specifically at the seed and start-up phases. These are typically pre-revenue or early-traction digital health ventures seeking initial institutional capital to fund clinical validation and regulatory certification. The cheque size is commensurate with French early-stage rounds in this sector, generally below €2 million per initial entry.
Which sectors and geographies does Majycc eSante Invest focus on?
Majycc eSante Invest is exclusively focused on digital health — software and technology products that operate within regulated healthcare environments, including telemedicine, clinical workflow tools, and patient-data platforms. Geographically, the firm concentrates on France as its home market, with additional activity in Belgium, Switzerland, and francophone North Africa where shared language and similar regulatory frameworks apply.
Does Majycc eSante Invest operate as a venture capital fund or a holding company?
Majycc eSante Invest operates as a private equity firm making direct equity investments into portfolio companies, rather than as a fund-of-funds or a corporate venture arm. Its structure is that of a specialist early-stage investor deploying proprietary capital or managed commitments into a single-sector digital health portfolio.
How does Majycc eSante Invest source its deal flow?
Given its narrow mandate in French and francophone digital health, the firm's deal flow likely originates through deep clinical and hospital-system networks, relationships with medical-technology incubators, and France's publicly supported e-health innovation programs. Sourcing is probably relationship-driven rather than auction-based, reflecting the small, specialized community of practice around digital health in the French ecosystem.
What makes Majycc eSante Invest structurally distinct from other European early-stage funds?
The firm's structural differentiator is its exclusive concentration on digital health — it does not diversify across other technology verticals, life sciences, or generalist consumer tech. Most European early-stage funds spread bets across digital, deeptech, and biotech to manage binary regulatory risk; Majycc eSante instead bets that deep domain expertise in a single regulated vertical will produce better sourcing and underwriting outcomes.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: